• Home
  • About
  • People
    • Our People
    • Shane Entriken
    • Philip Lucas
    • Stuart Mengler
    • Michael Panegyres
    • Stephanie Rowland
    • Paul Sartori
    • Garry Claxton
  • Expertise
    • Our Expertise
    • Corporate
    • Mining & Resources
    • Property
    • Intellectual Property & Technology
    • Workplace Relations, Health & Safety
  • News
  • Careers
  • Contact
Boutique / Legal / Advisory
24 Oct 2019

Allion acts for Lions Eye Institute

By allionpartners in Default

Allion has acted for the Lions Eye Institute, a not-for-profit medical research institution, on the launch of its commercial collaboration with Phylogica Limited (ASX: PYC), via formation of a new subsidiary, Vision Pharma. Phylogica, trading as PYC Therapeutics, has been listed on the ASX since 2005.

The collaboration will involve the development and commercialisation of precision medicines and treatment for the leading cause of childhood blindness with a new Australian-developed drug delivery platform. With no existing treatment options available for the disease, it is thought the therapy’s potential target market could top $1 billion per year.

Post navigation

Previous Post Previous post:
Allion acts for Geopacific Resources (ASX: GPR) on A$40M capital raising
Next Post Next post:
Allion acts on sale of PumpnSeal

Articles by Year

  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
Terms of Use & Privacy | design by JAZ